Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for PTSD? antidepressant vilazodone put to the test

NCT ID NCT05948579

Not yet recruiting Symptom relief Sponsor: Global Coalition for Adaptive Research Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 study tests whether the antidepressant vilazodone can safely reduce PTSD symptoms in 200 active-duty service members, veterans, and civilians. Participants receive either vilazodone or a placebo for 12 weeks, with symptom severity measured using a standard PTSD scale. The goal is to see if vilazodone improves symptoms without increasing suicidal thoughts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Vilazodone (an antidepressant)
What this could lead to
If it works, this could provide a new medication option to reduce PTSD symptoms in military and civilian populations.
What could go wrong
This is an early Phase 2 trial with only 200 participants, so results may not apply broadly. Vilazodone may cause side effects like nausea or insomnia, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-TRAUMATIC STRESS DISORDER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.